---
schema_version: "secwatch.filing_event.v1"
accession: "0001860782-24-000007"
form_type: "8-K"
ticker: null
cik: "0001860782"
company_name: "2seventy bio, Inc."
filed_at: "2024-01-30T23:59:59+00:00"
generated_at: "2026-06-06T15:15:22.028327+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# 2seventy bio sells R&D to Regeneron ($5M), focuses on Abecma; cuts workforce ~14%

## Summary
- Asset sale to Regeneron for $5M upfront, $10M milestone, royalties; ~160 employees transition; sublease facilities.
- Workforce reduction of ~14%, remaining ~65 employees; one-time restructuring costs ~$8M.
- Expected annual cost savings of ~$150M in 2024 and ~$200M in 2025; cash runway extended beyond 2027.
- CEO Nick Leschly resigns upon closing, becomes Chair; COO Chip Baird named CEO; Victoria Eatwell named CFO.
- Focus exclusively on Abecma with BMS; awaiting ODAC/PDUFA for potential third-line approval in 2024.

## SEC filing metadata
- accession: 0001860782-24-000007
- form_type: 8-K
- cik: 0001860782
- company_name: 2seventy bio, Inc.
- filed_at: 2024-01-30T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/tvst-20240128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001860782-24-000007
- JSON: https://secwatch.observer/filing/0001860782-24-000007.json
- Plain text: https://secwatch.observer/filing/0001860782-24-000007.txt

## Key facts
- Executive change
  Victoria Eatwell was appointed as Chief Financial Officer at 2seventy bio, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On January 29, 2024, the Board appointed Victoria Eatwell as the chief financial officer of the Company, effective as of the date of the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm
- Executive change
  Nick Leschly resigned as President and Chief Executive Officer at 2seventy bio, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: On January 29, 2024, Nick Leschly informed the Company of his resignation as the Company’s president and chief executive officer effective upon the date of the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm
- Executive change
  William D. Baird, III was appointed as President and Chief Executive Officer at 2seventy bio, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On January 29, 2024, the Board appointed William D. Baird, III as the president and chief executive officer of the Company, effective as of the date of the Closing.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm
- Material Agreements
  2seventy bio, Inc. entered into Purchase Agreement with Regeneron Pharmaceuticals, Inc. valued at $5 million in cash (effective 2024-01-29).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Regeneron Pharmaceuticals, Inc.
  - Value: $5 million in cash
  - Effective: 2024-01-29
  source text: On January 29, 2024, 2seventy bio, Inc. (the “Company”) entered into an asset purchase agreement (the “Purchase Agreement”) with Regeneron Pharmaceuticals, Inc. (“Regeneron”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm
- Restructurings & Charges
  2seventy bio, Inc. announced a restructuring with charges of approximately $8 million affecting the entire company (approximately 14%).
  - Type: restructuring
  - Charge: approximately $8 million
  - Affected area: the entire company
  - Headcount: approximately 14%
  source text: complete by the end of the second quarter of 2024. In connection with the workforce reduction and restructuring, the Company expects to incur one-time costs of approximately $8 million, primarily in the first half of 2024, relating to severance and retention packages and related benefits. The estimates of expenses and cash costs that the Company expects to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1860782/000186078224000007/0001860782-24-000007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.